Clin2
NCT05098210Possibly a fitRecruiting

Personalized vaccine made from your tumor’s new immune targets

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous MelanomaLocally Advanced Mucosal MelanomaMetastatic Acral MelanomaMetastatic Conjunctival MelanomaMetastatic Cutaneous MelanomaMetastatic HER2-Negative Breast Carcinoma

Treatments studied

Part of Cancer, Lungs & breathing, Skin clinical trials.

This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
28 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Be age 18 or older and able to do daily activities at a moderate level (ECOG 0–2).
  • Have measurable cancer that doctors can track on scans, and be able to get enough tumor tissue (through biopsy or surgery) for vaccine planning.
  • Have adequate blood counts and kidney/liver function based on lab tests (for example, creatinine and bilirubin within allowed ranges).
  • Have lungs that are stable enough for treatment (no active/interfering lung inflammation; oxygen level generally at least 92% on room air).
  • Have had standard cancer treatments for your specific cancer type, and your cancer must still be present or have come back after prior therapy (details depend on melanoma vs breast vs lung cancer).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05269381Recruiting· Phase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors

This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.

Jacksonville, Florida
NCT06324240Recruiting· Phase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer

This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.

Atlanta, Georgia
NCT05475106Recruiting· Early Phase 1
Personalized vaccine using tumor peptide targets and an immune booster

This early-phase trial tests a personalized immune treatment made from your tumor’s specific “neoantigen” targets (small pieces the immune system can recognize), plus an immune-boosting medicine. It aims to help control certain cancers by training your immune system to attack your tumor.

Tijuana, Estado de Baja California
NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets

This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.

Nanchang, Jiangxi
NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.

Shanghai, Shanghai Municipality
NCT06195293Recruiting· Phase 1
Personalized cancer vaccine for advanced solid tumors

This trial tests a personalized vaccine made from unique markers on your tumor cells (called neoantigens). The goal is to help your immune system fight the cancer more effectively. It is for people with advanced solid tumors who have not had gene therapy and are otherwise relatively healthy.

Guangzhou

Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.